These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11033573)

  • 1. On a reasonable disaggregate criterion of population bioequivalence admitting of resampling-free testing procedures.
    Wellek S
    Stat Med; 2000 Oct; 19(20):2755-67. PubMed ID: 11033573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An individual bioequivalence criterion: regulatory considerations.
    Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
    Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population and individual bioequivalence: lessons from real data and simulation studies.
    Zariffa NM; Patterson SD
    J Clin Pharmacol; 2001 Aug; 41(8):811-22. PubMed ID: 11504268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual bioequivalence revisited.
    Chen ML; Lesko LJ
    Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective assessment of the 75/75 rule in bioequivalence.
    Dobbins TW; Thiyagarajan B
    Stat Med; 1992 Jul; 11(10):1333-42. PubMed ID: 1518994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some statistical considerations on the FDA draft guidance for individual bioequivalence.
    Hsuan FC
    Stat Med; 2000 Oct; 19(20):2879-84. PubMed ID: 11033582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical evaluation of the scaled criterion for drug interchangeability.
    Li J; Chow SC
    J Biopharm Stat; 2017; 27(2):282-292. PubMed ID: 27937059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bootstrap procedure in individual bioequivalence.
    Shao J; Chow SC; Wang B
    Stat Med; 2000 Oct; 19(20):2741-54. PubMed ID: 11033572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability.
    Meyer MC; Straughn AB; Jarvi EJ; Patrick KS; Pelsor FR; Williams RL; Patnaik R; Chen ML; Shah VP
    Pharm Res; 2000 Apr; 17(4):381-4. PubMed ID: 10870979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMA's Average Bioequivalence Approach.
    Kurumaddali A; Christopher D; Sandell D; Strickland H; Morgan B; Bulitta J; Wiggenhorn C; Stein S; Lyapustina S; Hochhaus G
    AAPS PharmSciTech; 2019 Jul; 20(6):249. PubMed ID: 31286316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing for bioequivalence of highly variable drugs from TR-RT crossover designs with heterogeneous residual variances.
    Kang Q; Vahl CI
    Pharm Stat; 2017 Sep; 16(5):361-377. PubMed ID: 28620937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consideration of individual bioequivalence.
    Anderson S; Hauck WW
    J Pharmacokinet Biopharm; 1990 Jun; 18(3):259-73. PubMed ID: 2380920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of the Population Bioequivalence (PBE) Statistical Test Using an IPAC-RS Database of Delivered Dose from Metered Dose Inhalers.
    Morgan B; Chen S; Christopher D; Långström G; Wiggenhorn C; Burmeister Getz E; Beresford H; Hoffelder T; Acerbi D; Andrews S; Berry M; Dey M; Joshi K; McKenry M; Pertile M; Strickland H; Wilcox D; Lyapustina S
    AAPS PharmSciTech; 2018 Apr; 19(3):1410-1425. PubMed ID: 29435904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.
    Hauck WW; Hyslop T; Chen ML; Patnaik R; Williams RL
    Pharm Res; 2000 Apr; 17(4):375-80. PubMed ID: 10870978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalence tests for interchangeability based on two one-sided probabilities.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2014; 24(6):1332-48. PubMed ID: 25033074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.